Mantle Cell Lymphoma Care From Diagnosis Through Relapse: Expert Guidance on Applying the Latest Evidence

Explore key issues in the management of MCL in this comprehensive program designed to keep you abreast of rapidly evolving treatment strategies. Gain insights on new developments as they emerge with the CME-certified interactive module, downloadable slideset, short expert commentaries, and an Interactive Decision Support Tool that lets you compare your treatment choices for MCL patient scenarios you enter with those of 5 experts.
Julie M. Vose, MD, MBA

ClinicalThought: MCL Management

Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?

Julie M. Vose, MD, MBA Released: April 30, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
AstraZeneca
Pharmacyclics Inc.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?